Cargando…
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study
Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options. This phase II study evaluated the efficacy and safety of sugemalimab, an anti–PD-L1 monoclonal antibody, in R/R ENKTL. METHODS: Eligible...
Autores principales: | Huang, Huiqiang, Tao, Rong, Hao, Siguo, Yang, Yu, Cen, Hong, Zhou, Hui, Guo, Ye, Zou, Liqun, Cao, Junning, Huang, Yunhong, Jin, Jie, Zhang, Liling, Yang, Haiyan, Xing, Xiaojing, Zhang, Huilai, Liu, Yanyan, Ding, Kaiyang, Qi, Qinzhou, Zhu, Xiaoli, Zhu, Dan, Wang, Siyuan, Fang, Teng, Dai, Hangjun, Shi, Qingmei, Yang, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414714/ https://www.ncbi.nlm.nih.gov/pubmed/36996373 http://dx.doi.org/10.1200/JCO.22.02367 |
Ejemplares similares
-
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial
por: Gong, Jifang, et al.
Publicado: (2022) -
P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Huilai, et al.
Publicado: (2023) -
Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
por: Zheng, Zhiwei, et al.
Publicado: (2022) -
Gemstone spectral imaging in lung cancer: A preliminary study
por: Jia, Yulin, et al.
Publicado: (2018) -
Clinical relevance of gemstone spectral CT in the diagnosis of carotid atherosclerosis
por: Wang, Jing-Jian, et al.
Publicado: (2017)